製品番号: HY-N0191

Andrographolide

(別名: Andrographis; アンドログラホリド)

35 Cited Publications

カスタマーレビュー

Based on 35 publication(s) in Google Scholar

Andrographolide is a NF-κB inhibitor, which inhibits NF-κB activation through covalent modification of a cysteine residue on p50 in endothelial cells without affecting IκBα degradation or p50/p65 nuclear translocation. Andrographolide has antiviral effects.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.74%
CAS 番号: 5508-58-7
分子式: C₂₀H₃₀O₅
分子量:350.45

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Andrographolide 構造式

CAS 番号: 5508-58-7

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
- 臨床実験
化学情報
Publications (35)
溶剤 & 溶解度
- 体外
- 体内
プロトコル
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target^[1]

p50

NF-κB アイソフォーム固有の製品をすべて表示 :

Parasite アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
A2058	IC₅₀	26 μM Compound: 4; AGL	Cytotoxicity against human A2058 cells incubated for 48 hrs by MTT assay Cytotoxicity against human A2058 cells incubated for 48 hrs by MTT assay	[PMID: 33289552]
A498	GI₅₀	3 μM Compound: 1	Growth inhibition of human A498 cells Growth inhibition of human A498 cells	[PMID: 31151068]
A549	GI₅₀	13.37 μM Compound: 1	Growth inhibition of human A549 cells after 72 hrs by SRB assay Growth inhibition of human A549 cells after 72 hrs by SRB assay	[PMID: 23768904]
A549	GI₅₀	13.37 μM/L Compound: 1	Growth inhibition of human A549 cells after 72 hrs by SRB assay Growth inhibition of human A549 cells after 72 hrs by SRB assay	[PMID: 23768904]
A549	IC₅₀	27.9 μM Compound: 1	Cytotoxicity against human A549 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human A549 cells assessed as reduction in cell viability by SRB assay	[PMID: 28755636]
A549	IC₅₀	32.02 μM Compound: 1	Anticancer activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Anticancer activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 32527561]
A549	IC₅₀	12.15 μM Compound: 1	Cytotoxicity against human A549 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human A549 cells assessed as reduction in cell viability by SRB assay	[PMID: 33316411]
A549	IC₅₀	9.71 μg/mL Compound: 1	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	10.1039/C4MD00566J
ACHN	IC₅₀	3.03 μg/mL Compound: 1	Cytotoxicity against human ACHN cells by MTT assay Cytotoxicity against human ACHN cells by MTT assay	10.1039/C4MD00566J
B16	IC₅₀	7.54 μg/mL Compound: 1	Cytotoxicity against mouse B16 cells by MTT assay Cytotoxicity against mouse B16 cells by MTT assay	10.1039/C4MD00566J
BMDM	IC₅₀	0.55 μM Compound: AM-721/20681006	Inhibition of GST-tagged recombinant RANKL/M-CSF-induced osteoclastogenesis in C57BL/6 mouse bone marrow derived macrophages assessed as TRAcP enzymatic activity incubated for 5 days with subsequent replenishment of media for 2 days and measured by leucoc Inhibition of GST-tagged recombinant RANKL/M-CSF-induced osteoclastogenesis in C57BL/6 mouse bone marrow derived macrophages assessed as TRAcP enzymatic activity incubated for 5 days with subsequent replenishment of media for 2 days and measured by leucoc	[PMID: 33158578]
BMMC	CC₅₀	10.31 μM Compound: 1; AP	Cytotoxicity against C57BL/6 mouse BMM cells assessed as reduction in cell viability measured after 48 hrs in presence of M-CSF by CCK8 assay Cytotoxicity against C57BL/6 mouse BMM cells assessed as reduction in cell viability measured after 48 hrs in presence of M-CSF by CCK8 assay	[PMID: 33485256]
BMMC	IC₅₀	1.01 μM Compound: 1; AP	Anti-osteoporosis activity in C57BL/6 mouse BMM cells assessed as inhibition of M-CSF/RANKL-induced osteoclastogenesis by measuring reduction in multinucleated TRAP+ cells incubated for 5 days with media replenishment for every 48 hrs measured by TRAP-sta Anti-osteoporosis activity in C57BL/6 mouse BMM cells assessed as inhibition of M-CSF/RANKL-induced osteoclastogenesis by measuring reduction in multinucleated TRAP+ cells incubated for 5 days with media replenishment for every 48 hrs measured by TRAP-sta	[PMID: 33485256]
BT-549	IC₅₀	23.2 μM Compound: Andrographolide	Antiproliferative activity against human BT-549 cells Antiproliferative activity against human BT-549 cells	[PMID: 34315039]
Col2	ED₅₀	13.6 μM Compound: 1	Cytotoxicity against human Col2 cells by SRB assay Cytotoxicity against human Col2 cells by SRB assay	[PMID: 22154665]
DU-145	GI₅₀	15.99 μM Compound: 1	Growth inhibition of human DU145 cells after 72 hrs by SRB assay Growth inhibition of human DU145 cells after 72 hrs by SRB assay	[PMID: 23768904]
DU-145	GI₅₀	15.99 μM/L Compound: 1	Growth inhibition of human DU145 cells after 72 hrs by SRB assay Growth inhibition of human DU145 cells after 72 hrs by SRB assay	[PMID: 23768904]
DU-145	GI₅₀	3 μM Compound: 1	Growth inhibition of human DU145 cells Growth inhibition of human DU145 cells	[PMID: 31151068]
HCT-116	IC₅₀	23.93 μM Compound: 1	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 23628335]
HCT-116	GI₅₀	4.5 μM Compound: 21; AGP	Antiproliferative activity against human HCT-116 cells harboring KRAS G13D mutant assessed as cell growth inhibition measured after 96 hrs by MTT assay Antiproliferative activity against human HCT-116 cells harboring KRAS G13D mutant assessed as cell growth inhibition measured after 96 hrs by MTT assay	[PMID: 33228976]
HCT-116	IC₅₀	>40 μM Compound: 4; AGL	Cytotoxicity against human HCT-116 cells Cytotoxicity against human HCT-116 cells	[PMID: 33289552]
HCT-116	IC₅₀	31.8 μM Compound: Andrographolide	Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 34315039]
HCT-116	IC₅₀	19 μg/mL Compound: Andro	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by WST-1 assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by WST-1 assay	[PMID: 38306267]
HEK293	IC₅₀	49.6 μM Compound: 1	Inhibition of TNF-alpha-stimulated NF-kappaB p50 (unknown origin) expressed in HEK293 cells preincubated for 4 hrs followed by TNF-alpha challenge measured after 24 hrs by secreted alkaline phosphatase reporter assay Inhibition of TNF-alpha-stimulated NF-kappaB p50 (unknown origin) expressed in HEK293 cells preincubated for 4 hrs followed by TNF-alpha challenge measured after 24 hrs by secreted alkaline phosphatase reporter assay	[PMID: 25615020]
HEK293	CC₅₀	26.25 μM Compound: 1	Cytotoxicity against HEK293 cells assessed as reduction in cell viability measured after 24 hrs by Celltiter-glo assay Cytotoxicity against HEK293 cells assessed as reduction in cell viability measured after 24 hrs by Celltiter-glo assay	[PMID: 32712435]
HeLa	IC₅₀	23 μM Compound: Andrographolide	Antiviral activity against DENV2 infected in human HeLa cells incubated for 1 hrs by plaque assay Antiviral activity against DENV2 infected in human HeLa cells incubated for 1 hrs by plaque assay	[PMID: 34315039]
HeLa	IC₅₀	10.42 μg/mL Compound: 1	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	10.1039/C4MD00566J
HepG2	IC₅₀	9.7 μM Compound: 1	Antagonist activity at Gal4 DBD-fused human FXR LBD expressed in human HepG2 cells after 8 hrs by luciferase reporter gene assay Antagonist activity at Gal4 DBD-fused human FXR LBD expressed in human HepG2 cells after 8 hrs by luciferase reporter gene assay	[PMID: 31151068]
HepG2	IC₅₀	21 μM Compound: Andrographolide	Antiviral activity against DENV2 infected in human HepG2 cells incubated for 1 hrs by plaque assay Antiviral activity against DENV2 infected in human HepG2 cells incubated for 1 hrs by plaque assay	[PMID: 34315039]
HepG2 2.2.15	CC₅₀	198 μM Compound: 1b	Cytotoxicity against human HepG2.2.15 cells by MTT assay Cytotoxicity against human HepG2.2.15 cells by MTT assay	[PMID: 24731274]
HepG2 2.2.15	IC₅₀	54.1 μM Compound: 1b	Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of DNA replication Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of DNA replication	[PMID: 24731274]
HK-2	IC₅₀	30.6 μM Compound: Andrographolide	Antiproliferative activity against human HK-2 cells Antiproliferative activity against human HK-2 cells	[PMID: 34315039]
HL-60	GI₅₀	9.33 μM Compound: 7	Antiproliferative activity against human HL60 cells by trypan blue assay Antiproliferative activity against human HL60 cells by trypan blue assay	[PMID: 18357994]
HL-60	IC₅₀	27 μM Compound: 6	Cytotoxicity against human HL60 cells after 18 hrs by annexin-V labeling-based flow cytometry Cytotoxicity against human HL60 cells after 18 hrs by annexin-V labeling-based flow cytometry	[PMID: 22985027]
HL-60	IC₅₀	2.4 μM Compound: 4; AGL	Antiproliferative activity against human HL-60 cells incubated for 24 hrs by MTT assay Antiproliferative activity against human HL-60 cells incubated for 24 hrs by MTT assay	[PMID: 33289552]
HL-60	IC₅₀	7 μM Compound: 4; AGL	Antiproliferative activity against human HL-60 cells Antiproliferative activity against human HL-60 cells	[PMID: 33289552]
HT-29	IC₅₀	9.34 μM Compound: 1	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability by SRB assay	[PMID: 28755636]
HT-29	IC₅₀	8.91 μM Compound: 1	Anticancer activity against human HT-29 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Anticancer activity against human HT-29 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 32527561]
HT-29	IC₅₀	>30 μM Compound: 4; AGL	Cytotoxicity against human HT-29 cells incubated for 48 hrs by MTT assay Cytotoxicity against human HT-29 cells incubated for 48 hrs by MTT assay	[PMID: 33289552]
HT-29	IC₅₀	10.8 μM Compound: 1	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability by SRB assay	[PMID: 33316411]
HT-29	IC₅₀	10 μg/mL Compound: Andro	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability measured after 48 hrs by WST-1 assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability measured after 48 hrs by WST-1 assay	[PMID: 38306267]
HuCC-A1	IC₅₀	23.61 μM Compound: 1	Anticancer activity against human HuCCa1 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Anticancer activity against human HuCCa1 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 32527561]
IEC-6	IC₅₀	8.26 μg/mL Compound: 1	Cytotoxicity against rat IEC-6 cells by MTT assay Cytotoxicity against rat IEC-6 cells by MTT assay	10.1039/C4MD00566J
K562	IC₅₀	41.85 μM Compound: Andrographolide	Antiproliferative activity against human K562 cells assessed as growth inhibition after 48 hrs by MTS-PMS assay Antiproliferative activity against human K562 cells assessed as growth inhibition after 48 hrs by MTS-PMS assay	[PMID: 20974534]
K562	IC₅₀	23.66 μM Compound: Andrographolide	Antiproliferative activity against human K562 cells assessed as reduction in cell viability by MTT assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability by MTT assay	[PMID: 34315039]
KB	ED₅₀	27.37 μM Compound: 1	Cytotoxicity against human KB cells by SRB assay Cytotoxicity against human KB cells by SRB assay	[PMID: 22154665]
KB	GI₅₀	13.18 μM Compound: 1	Growth inhibition of human KB cells after 72 hrs by SRB assay Growth inhibition of human KB cells after 72 hrs by SRB assay	[PMID: 23768904]
KB	GI₅₀	13.18 μM/L Compound: 1	Growth inhibition of human KB cells after 72 hrs by SRB assay Growth inhibition of human KB cells after 72 hrs by SRB assay	[PMID: 23768904]
KB	IC₅₀	27.37 μM Compound: 1	Cytotoxicity against human KB cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human KB cells assessed as reduction in cell viability by SRB assay	[PMID: 28755636]
KB	IC₅₀	31.73 μM Compound: 1	Anticancer activity against human KB cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Anticancer activity against human KB cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 32527561]
KB	IC₅₀	41.53 μM Compound: 1	Cytotoxicity against human KB cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human KB cells assessed as reduction in cell viability by SRB assay	[PMID: 33316411]
KBM5	IC₅₀	8.5 μM Compound: Andrographolide	Antiproliferative activity against human KBM5 cells assessed as reduction in cell viability by MTT assay Antiproliferative activity against human KBM5 cells assessed as reduction in cell viability by MTT assay	[PMID: 34315039]
L02	CC₅₀	14.68 μM Compound: 1	Cytotoxicity against human L02 cells assessed as reduction in cell viability measured after 24 hrs by Celltiter-glo assay Cytotoxicity against human L02 cells assessed as reduction in cell viability measured after 24 hrs by Celltiter-glo assay	[PMID: 32712435]
L132	IC₅₀	53.8 μM Compound: Andrographolide	Antiproliferative activity against human L-132 cells assessed as growth inhibition after 48 hrs by MTS-PMS assay Antiproliferative activity against human L-132 cells assessed as growth inhibition after 48 hrs by MTS-PMS assay	[PMID: 20974534]
L5178Y	IC₅₀	14.52 μM Compound: 1	Antiproliferative activity against mouse L5178Y cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against mouse L5178Y cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 38665830]
L5178Y	IC₅₀	14.95 μM Compound: 1	Reversal of multidrug resistance in multidrug resistant mouse L5178Y cells transfected with human ABCB1 assessed as reduction in cell viability incubated for 72 hrs by MTT assay Reversal of multidrug resistance in multidrug resistant mouse L5178Y cells transfected with human ABCB1 assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 38665830]
Lu1	ED₅₀	12.98 μM Compound: 1	Cytotoxicity against human Lu1 cells by SRB assay Cytotoxicity against human Lu1 cells by SRB assay	[PMID: 22154665]
MCF7	ED₅₀	15.4 μM Compound: 1	Cytotoxicity against human MCF7 cells by SRB assay Cytotoxicity against human MCF7 cells by SRB assay	[PMID: 22154665]
MCF7	IC₅₀	>66 μM Compound: 1	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 23628335]
MCF7	IC₅₀	30.82 μM Compound: 1	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 25913115]
MCF7	IC₅₀	15.4 μM Compound: 1	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by SRB assay	[PMID: 28755636]
MCF7	GI₅₀	3 μM Compound: 1	Growth inhibition of human MCF7 cells Growth inhibition of human MCF7 cells	[PMID: 31151068]
MCF7	IC₅₀	8.48 μM Compound: 1	Anticancer activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Anticancer activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 32527561]
MCF7	IC₅₀	15 μM Compound: 4; AGL	Antiproliferative activity against human MCF7 cells incubated for 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells incubated for 48 hrs by SRB assay	[PMID: 33289552]
MCF7	IC₅₀	29.06 μM Compound: 1	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by SRB assay	[PMID: 33316411]
MCF7	IC₅₀	35.1 μM Compound: Andrographolide	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 34315039]
MDA-MB-231	IC₅₀	16.55 μM Compound: 1	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 25913115]
MDA-MB-231	IC₅₀	>30 μM Compound: 4; AGL	Cytotoxicity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay	[PMID: 33289552]
MDA-MB-231	IC₅₀	20.3 μM Compound: Andrographolide	Antitumor activity against human MDA-MB-231 cells assessed as tumor growth inhibition Antitumor activity against human MDA-MB-231 cells assessed as tumor growth inhibition	[PMID: 34315039]
MDA-MB-361	IC₅₀	31.5 μM Compound: Andrographolide	Antitumor activity against human MDA-MB-361 cells assessed as tumor growth inhibition Antitumor activity against human MDA-MB-361 cells assessed as tumor growth inhibition	[PMID: 34315039]
MIA PaCa-2	IC₅₀	21.07 μM Compound: 1; Andro	Antiproliferative activity against human MIA PaCa-2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human MIA PaCa-2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 38171253]
MT2	IC₅₀	140 μM Compound: Andrographolide	Antiviral activity against HIV infected in human MT2 cells Antiviral activity against HIV infected in human MT2 cells	[PMID: 34315039]
NCI/ADR-RES	GI₅₀	3 μM Compound: 1	Growth inhibition of human MCF7/ADR cells Growth inhibition of human MCF7/ADR cells	[PMID: 31151068]
NIH3T3	IC₅₀	44.5 μM Compound: Andrographolide	Antiproliferative activity against mouse NIH/3T3 cells assessed as growth inhibition after 48 hrs by MTS-PMS assay Antiproliferative activity against mouse NIH/3T3 cells assessed as growth inhibition after 48 hrs by MTS-PMS assay	[PMID: 20974534]
NIH3T3	IC₅₀	95.28 μM Compound: 1	Antifibrotic activity against mouse NIH/3T3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Antifibrotic activity against mouse NIH/3T3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 30144698]
NTUB1	IC₅₀	32.52 μM Compound: 1	Cytotoxicity against human NTUB1 cells after 48 hrs by MTT assay Cytotoxicity against human NTUB1 cells after 48 hrs by MTT assay	[PMID: 25913115]
P388	ED₅₀	2.25 μM Compound: 1	Cytotoxicity against mouse P388 cells by SRB assay Cytotoxicity against mouse P388 cells by SRB assay	[PMID: 22154665]
P388	IC₅₀	2.25 μM Compound: 1	Cytotoxicity against mouse P388 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against mouse P388 cells assessed as reduction in cell viability by SRB assay	[PMID: 28755636]
P388	IC₅₀	6.52 μM Compound: 1	Anticancer activity against mouse P388 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay Anticancer activity against mouse P388 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay	[PMID: 32527561]
P388	IC₅₀	2.9 μM Compound: 4; AGL	Antiproliferative activity against mouse P388 cells Antiproliferative activity against mouse P388 cells	[PMID: 33289552]
PANC-1	IC₅₀	20.41 μM Compound: 1; Andro	Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 38171253]
PC-3	IC₅₀	30 μM Compound: Andrographolide	Growth inhibition of human PC3 cells after 48 hrs by MTT assay Growth inhibition of human PC3 cells after 48 hrs by MTT assay	[PMID: 30108837]
RAW264.7	IC₅₀	6.96 μM Compound: 21	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method	[PMID: 22264489]
RAW264.7	IC₅₀	8.81 μM Compound: 1	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 3 hrs followed by LPS addition and measured after 24 hrs by griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 3 hrs followed by LPS addition and measured after 24 hrs by griess assay	[PMID: 30419492]
RAW264.7	IC₅₀	14.42 μM Compound: Andrographolide	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 3 hrs followed by LPS addition measured after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 3 hrs followed by LPS addition measured after 24 hrs by Griess assay	[PMID: 31009914]
RAW264.7	CC₅₀	10 μM Compound: 1	Cytotoxicity against BSO-treated mouse RAW264.7 cells assessed as reduction cell viability measured after 24 hrs by Celltiter-glo assay Cytotoxicity against BSO-treated mouse RAW264.7 cells assessed as reduction cell viability measured after 24 hrs by Celltiter-glo assay	[PMID: 32712435]
SK-OV-3	GI₅₀	3 μM Compound: 1	Growth inhibition of human SKOV3 cells Growth inhibition of human SKOV3 cells	[PMID: 31151068]
SW-620	GI₅₀	3 μM Compound: 1	Growth inhibition of human SW620 cells Growth inhibition of human SW620 cells	[PMID: 31151068]
T47D	IC₅₀	32.4 μM Compound: Andrographolide	Antiproliferative activity against human T47D cells Antiproliferative activity against human T47D cells	[PMID: 34315039]
THP-1	IC₅₀	6.69 μM Compound: Andrographolide	Antiproliferative activity against human THP1 cells assessed as growth inhibition after 48 hrs by MTS-PMS assay Antiproliferative activity against human THP1 cells assessed as growth inhibition after 48 hrs by MTS-PMS assay	[PMID: 20974534]
TZM	CC₅₀	1696 μM Compound: 1, andro	Cytotoxicity against human TZM-bl cells after 48 hrs by MTT assay Cytotoxicity against human TZM-bl cells after 48 hrs by MTT assay	[PMID: 22858223]
U-251	GI₅₀	3 μM Compound: 1	Growth inhibition of human U251 cells Growth inhibition of human U251 cells	[PMID: 31151068]
U-937	IC₅₀	12.87 μM Compound: Andrographolide	Antiproliferative activity against human U937 cells assessed as growth inhibition after 48 hrs by MTS-PMS assay Antiproliferative activity against human U937 cells assessed as growth inhibition after 48 hrs by MTS-PMS assay	[PMID: 20974534]
Vero	IC₅₀	100 μM Compound: 2	Antiviral activity against West Nile virus Kunjin infected in African green monkey Vero cells assessed as reduction in plague formation incubated for 72 hrs by immunofluorescence assay Antiviral activity against West Nile virus Kunjin infected in African green monkey Vero cells assessed as reduction in plague formation incubated for 72 hrs by immunofluorescence assay	[PMID: 31553187]
Vero	CC₅₀	>200 μM Compound: 1	Cytotoxicity against african green monkey Vero cells incubated for 96 hrs Cytotoxicity against african green monkey Vero cells incubated for 96 hrs	[PMID: 36055002]

体外実験

Andrographolide (AP) concentration-dependently suppresses receptor activator of nuclear factor kappa B ligand (RANKL)-mediated osteoclast differentiation and bone resorption in vitro and reduces the expression of osteoclast-specific markers. Andrographolide attenuates inflammation by inhibition of TNFα-induced NF-κB activation through covalent modification of reduced Cys⁶² of p50, without affecting IκBα degradation or p50/p65 nuclear translocation. Andrographolide also inhibits the ERK/MAPK signalling pathway without affecting p38 or JNK signalling. Andrographolide inhibits osteoclast differentiation of RAW 264.7 cells in a concentration-dependent manner. Andrographolide suppresses osteoclast formation in a concentration-dependent manner without any obvious cytotoxic effects, in both BMMs and RAW 264.7 cells. Andrographolide treatment substantially reduces the area of bone resorption. Only approximately 30% of the bone resorption observed in the control group is achieved after treatment with 2.5?μM Andrographolide. Osteoclastic bone resorption is almost completely inhibited after treatment with 10?μM Andrographolide^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Treatment with Andrographolide (5 or 30?mg/kg) reduces the extent of bone loss induced by LPS. Moreover, Andrographolide slightly increases the BMD and cortex thickness compared to LPS treatment. Histological examination confirms the protective effects of Andrographolide on LPS-induced bone loss. LPS injection leads to inflammatory bone erosion and increased numbers of TRAP-positive osteoclasts^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

臨床実験

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

化学情報

CAS 番号 5508-58-7
性状 Solid
分子量 350.45
分子式 C₂₀H₃₀O₅
Color White to off-white
SMILES

O=C1OC[C@@H](O)/C1=C\C[C@@H]2C(CC[C@]3([H])[C@](C)(CO)[C@H](O)CC[C@@]23C)=C
別名

Andrographis; アンドログラホリド
Structure Classification
- Terpenoids
- Diterpenoids
Initial Source
- Plants
- Acanthaceae
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (35)

All Cell Proliferation/Viability AssayELISAWBIF

Sort by:

Journal Impact Factor

Cell Res

Tau is a receptor with low affinity for glucocorticoids and is required for glucocorticoid-induced bone loss. [Abstract]

2025 Jan;35(1):23-44. PMID: 39743632
Adv Sci (Weinh)

Targeted SPP1 Inhibition of Tumor-Associated Myeloid Cells Effectively Decreases Tumor Sizes. [Abstract]

2024 Dec 5:e2410360. PMID: 39639496
Nucleic Acids Res

COVID19 Drug Repository: text-mining the literature in search of putative COVID19 therapeutics. [Abstract]

2021 Jan 8;49(D1):D1113-D1121. PMID: 33166390
Phytomedicine

Fangchinoline suppresses nasopharyngeal carcinoma progression by inhibiting SQLE to regulate the PI3K/AKT pathway dysregulation. [Abstract]

2025 May:140:156484. PMID: 40090046
Phytomedicine

Andrographolide promoted ferroptosis to repress the development of non-small cell lung cancer through activation of the mitochondrial dysfunction. [Abstract]

2023 Jan:109:154601. PMID: 36610134
Int J Pharm

Norcantharidin liposome emulsion hybrid delivery system enhances PD-1/PD-L1 immunotherapy by agonizing the non-canonical NF-κB pathway. [Abstract]

2022 Nov 25:628:122361. PMID: 36332828
Drug Des Devel Ther

Andrographolide Inhibits Static Mechanical Pressure-Induced Intervertebral Disc Degeneration via the MAPK/Nrf2/HO-1 Pathway. [Abstract]

2023 Feb 20:17:535-550. PMID: 36845666
Biofactors

Andrographolide Promotes Ferroptosis in Pancreatic Cancer via Targeting and Activating HSP90/GPX4 Ubiquitination. [Abstract]

2025 Nov-Dec;51(6):e70063. PMID: 41292183
Front Pharmacol

Positive Effect of Andrographolide Induced Autophagy on Random-Pattern Skin Flaps Survival. [Abstract]

2021 Mar 16;12:653035. PMID: 33796027
Int Immunopharmacol

Andrographolide attenuates PM2.5-induced blood-brain barrier damage via antioxidant and PI3K/AKT/mTOR/NRF2 pathways. [Abstract]

2025 May 7:157:114764. PMID: 40339493
Front Microbiol

Andrographolide Prevents EV-D68 Replication by Inhibiting the Acidification of Virus-Containing Endocytic Vesicles. [Abstract]

2018 Oct 8:9:2407. PMID: 30349523

Andrographolide purchased from MedChemExpress. Usage Cited in: Front Microbiol. 2018 Oct 8:9:2407. [Abstract]

RD cells are pretreated with andrographolide or DMSO vehicle overnight and subsequently infected with EV-D68. Immunoblotting of VP1 expression at 2, 4, 8, 12 h post-infection. There is an observable reduction in EV-D68 VP1 protein expression in ADO-treated cells compared to vehicle-treated cells on immunoblotting.

Andrographolide purchased from MedChemExpress. Usage Cited in: Front Microbiol. 2018 Oct 8:9:2407. [Abstract]

Immunofluorescence of VP1 expression at 10 h post-infection. There is an observable reduction in EV-D68 VP1 protein expression in ADO-treated cells compared to vehicle-treated cells on immunofluorescence assays

Andrographolide purchased from MedChemExpress. Usage Cited in: Front Microbiol. 2018 Oct 8:9:2407. [Abstract]

Fluorescence intensity peaked at around 2 h post-infection and is quickly quenched by 3 h post-infection in vehicle-treated RD cells. ADO-treated cells exhibit limited fluorescence.
J Cell Mol Med

Long non-coding RNA LINC00526 represses glioma progression via forming a double negative feedback loop with AXL. [Abstract]

2019 Aug;23(8):5518-5531. PMID: 31240814
iScience

2025 Dec 8.
J Inflamm Res

Andrographolide Attenuates Inflammation Due to Intra-Abdominal Sepsis by Enhancing Bacterial Clearance in Mice. [Abstract]

2023 Oct 6:16:4413-4423. PMID: 37822531
J Biol Chem

Andrographolide targets syndecan4 to impair its interaction with syntenin and inhibits the biogenesis of small extracellular vesicles. [Abstract]

2026 Jan 20:111182. PMID: 41570990
Oncol Rep

Andrographolide sensitizes human renal carcinoma cells to TRAIL‑induced apoptosis through upregulation of death receptor 4. [Abstract]

2020 Nov;44(5):1939-1948. PMID: 33000263
Circ J

2026 Apr 18. PMID: 42002911
Cell Signal

Paederia scandens-derived exosome-like nanoparticles as a delivery system for andrographolide to treat ulcerative colitis. [Abstract]

2025 Nov:135:112014. PMID: 40695370
Arch Pharm (Weinheim)

Design, synthesis, and characterization of PROTACs targeting the androgen receptor in prostate and lung cancer models. [Abstract]

2022 May;355(5):e2100467. PMID: 35128717
Med Oncol

Andrographolide elevates tumor necrosis factor-related apoptosis-inducing ligand lethality through reactive oxygen species accumulation and gasdermin E cleavage in breast cancer cells. [Abstract]

2022 Nov 9;40(1):11. PMID: 36352155
ChemMedChem

Andrographolide Derivatives Target the KEAP1/NRF2 Axis and Possess Potent Anti-SARS-CoV-2 Activity. [Abstract]

2022 Mar 4;17(5):e202100732. PMID: 35099120
Pathogens

2026 Feb;15(2):169.
J Pharm Pharmacol

Andrographolide attenuates oxidative stress and apoptosis in osteoporosis rats via MEK/ERK and Beclin-1/ATG-5-mediated autophagy pathway. [Abstract]

2025 Aug 4:rgaf052. PMID: 40757977
Naunyn Schmiedebergs Arch Pharmacol

Andrographolide blocked the progression of endometriosis by promoting ferroptosis via inhibiting anabolism of serine. [Abstract]

2025 Dec 18. PMID: 41408483
Genes (Basel)

Differential Expression of Key Oncogenic and Tumor Suppressor MicroRNAs Induced by Andrographolide in Androgen-Independent PC3 and Androgen-Dependent LNCaP Prostate Cancer Cells. [Abstract]

2025 Dec 17;16(12):1514. PMID: 41465187
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
Fitoterapia

Characterization of andrographolide-loaded exosome-like nanoparticles from Nauclea officinalis and their modulation of inflammatory and lipid metabolic pathologies in WRL68 cells. [Abstract]

2026 Apr:190:107179. PMID: 41850591
Ultrasound Med Biol

Can Viscoelasticity Measurements Obtained Through Shear-Wave US Elastography be used to Monitor Hepatic Ischemia-Reperfusion Injury and Treatment Response? An Animal Study. [Abstract]

2020 Sep;46(9):2464-2471. PMID: 32553529
Gene

Elucidation of the key therapeutic targets and potential mechanisms of Andrographolide multi-targets against osteoarthritis via network pharmacological analysis and experimental validation. [Abstract]

2024 Jun 15:911:148351. PMID: 38462021

Andrographolide purchased from MedChemExpress. Usage Cited in: Gene. 2024 Jun 15:911:148351. [Abstract]

Andrographolide (30 μM, 48 h) reversed SDF-1 (100 ng/mL, 48 h)-induced cell growth inhibition in chondrocytes.

Andrographolide purchased from MedChemExpress. Usage Cited in: Gene. 2024 Jun 15:911:148351. [Abstract]

Andrographolide (30 μM, 48 h) reversed the SDF-1 (100 ng/mL, 48 h)-induced decrease in COL2A1 and ACAN content in chondrocytes.

Andrographolide purchased from MedChemExpress. Usage Cited in: Gene. 2024 Jun 15:911:148351. [Abstract]

Andrographolide (30 μM, 48 h) reversed SDF-1 (100 ng/mL, 48 h)-induced expression of TNF-α, IL-6, and IL-1β in chondrocytes.

Andrographolide purchased from MedChemExpress. Usage Cited in: Gene. 2024 Jun 15:911:148351. [Abstract]

Andrographolide (30 μM, 48 h) reversed SDF-1 (100 ng/mL, 48 h)-induced expression of STAT3, TP53, JUN, HIF-1α, TGF-β1, and AKT1.
Biochem Biophys Res Commun

Andrographolide promotes lymphangiogenesis and lymphatic vessel remodeling to alleviate secondary lymphedema. [Abstract]

2024 May 25:723:150179. PMID: 38820623
Vet Parasitol

Cryptosporidium parvum downregulates miR-181d in HCT-8 cells via the p50-dependent TLRs/NF-κB pathway. [Abstract]

2022 May;305:109710. PMID: 35462275
J Gastrointest Oncol

Andrographolide potentiates anti-tumor immunity in colorectal cancer (CRC) by targeting voltage-dependent anion channel (VDAC) and activating the cGAS-STING axis. [Abstract]

2025 Aug 30;16(4):1550-1561. PMID: 40950339
J Orthop

Andrographolide suppresses fibrogenic phenotype of chondrocytes and ameliorates osteoarthritis by regulating miR-137/BMP7 axis. [Abstract]

2024 Nov 26:64:108-116. PMID: 39691644
Oxid Med Cell Longev

URB597 and Andrographolide Improve Brain Microvascular Endothelial Cell Permeability and Apoptosis by Reducing Oxidative Stress and Inflammation Associated with Activation of Nrf2 Signaling in Oxygen-Glucose Deprivation. [Abstract]

2022 May 12;2022:4139330. PMID: 35602108
Research Square Preprint

2021 Aug.

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (285.35 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.8535 mL

14.2674 mL

28.5347 mL

5 mM

0.5707 mL

2.8535 mL

5.7069 mL

10 mM

0.2853 mL

1.4267 mL

2.8535 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.13 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (7.13 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.13 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/saline water

Solubility: 2 mg/mL (5.71 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

プロトコル

Kinase Assay^[1]

In vitro osteoclastogenesis assays are preformed to examine the effects of Andrographolide on osteoclast differentiation. Bone marrow macrophages (BMM) cells are prepared. Briefly, cells extracted from the femur and tibiae of a 6-week-old C57/BL6 mouse are incubated in complete cell culture media and 30 ng/mL M-CSF in a T-75 cm² flask for proliferation. When changing the medium, the cells are washed in order to deplete residual stromal cells. After reaching 90% confluence, cells are washed with PBS three times and trypsinized for 30 min to harvest BMMs. Cells adhering to the bottom of the dish are classified as BMMs; these BMMs are plated in 96-well plates at a density of 8×10³ cells per well in triplicate and incubated in a humidified incubator containing 5% CO₂ at 37°C for 24 h. The cells are then treated with various concentrations of Andrographolide (0, 2.5, 5, or 10 μM) plus M-CSF (30 ng/mL) and RANKL (50 ng/mL). After 5 days, cells are fixed and stained for tartrate-resistant acid phosphatase (TRAP) activity. TRAP-positive multinucleated cells with more than five nuclei are counted as osteoclasts^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[1]

Effects of Andrographolide on cell proliferation are determined with a CCK-8. BMMs are plated in 96-well plates at a density of 3×10³ cells per well in triplicate. Twenty-four hours later, the cells are treated with increasing concentrations of Andrographolide (0, 2.5, 5, 10 or 20 μM) for 2 days. Next, 10 μL CCK-8 is added to each well, and the plates are then incubated at 37°C for an additional 2 h. The optical density (OD) is then measured with an ELX800 absorbance microplate reader at a wavelength of 450 nm (650 nm reference). The cell viability is calculated^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Mice^[1]
C57BL/6 mice (8 weeks old) are divided into four groups of seven mice each. Mice are injected i.p. with Andrographolide (5 or 30 mg/kg body weight) or PBS as a control 1 day before injection of LPS (5 μg/g body weight). Andrographolide or PBS is injected intraperitoneally every other day for 8 days. LPS is injected intraperitoneally on days one and four. All mice are killed 8 days after the initial LPS injection, and the left femurs of all animals are scanned with a high-resolution micro-CT at a resolution of 9 μm.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (284 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Zhai ZJ, et al. Andrographolide suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo. Br J Pharmacol. 2014 Feb;171(3):663-75. [Content Brief]

[2]. Gupta S, et al. Broad-spectrum antiviral properties of andrographolide. Arch Virol. 2017 Mar;162(3):611-623. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.8535 mL	14.2674 mL	28.5347 mL	71.3369 mL
	5 mM	0.5707 mL	2.8535 mL	5.7069 mL	14.2674 mL
	10 mM	0.2853 mL	1.4267 mL	2.8535 mL	7.1337 mL
	15 mM	0.1902 mL	0.9512 mL	1.9023 mL	4.7558 mL
	20 mM	0.1427 mL	0.7134 mL	1.4267 mL	3.5668 mL
	25 mM	0.1141 mL	0.5707 mL	1.1414 mL	2.8535 mL
	30 mM	0.0951 mL	0.4756 mL	0.9512 mL	2.3779 mL
	40 mM	0.0713 mL	0.3567 mL	0.7134 mL	1.7834 mL
	50 mM	0.0571 mL	0.2853 mL	0.5707 mL	1.4267 mL
	60 mM	0.0476 mL	0.2378 mL	0.4756 mL	1.1889 mL
	80 mM	0.0357 mL	0.1783 mL	0.3567 mL	0.8917 mL
	100 mM	0.0285 mL	0.1427 mL	0.2853 mL	0.7134 mL

Keywords

Andrographolide

35 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Andrographolide

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Medicine Food Homology Compound Library

Terpenoids Library

Pyroptosis Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Antiparasitic Compound library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Targeted Diversity Library

Anti-Liver Cancer Compound Library

Rare Diseases Drug Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Antiviral Traditional Chinese Medicine Active Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

FDA-Approved Anticancer Drug Library

Anti-Prostate Cancer Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Off-patent Drug Library

Cysteine Targeted Covalent Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

FDA-Approved Traditional Chinese Medicine Active Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Dietary Supplement Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

Flavor Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Cosmetic Ingredient Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Chinese Baijiu Compound Library

Natural Product Diversity Scaffold Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

MedChemExpress（MCE）の使用を引用している文献 Andrographolide